Wednesday, August 12, 2009 7:07:59 AM
WEST HAVEN, Conn., Aug 12, 2009 (BUSINESS WIRE) -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company's nanoviricides(TM) anti-Herpes drug candidates.
"Over 90% of the people are infected with Herpes, whether they know it or not," said Dr. Kousoulas, adding "it can manifest as cold sores or genital herpes. [These manifestations] can be very painful, especially for women." He also commented that "Unlike true love, herpes is forever," referring to the fact that the herpes virus goes dormant in the body between recurrent manifestations, and that there is at present no cure for herpes.
"A nanoviricide drug could be an important breakthrough," he said, explaining, "the duration of a cold sore could be reduced drastically, from a month to just a few days [by applying a nanoviricide skin cream]," based on studies conducted in the laboratories at the Louisiana State University's (LSU) Division of Biotechnology and Molecular Medicine (BIOMMED). In cell culture testing, his laboratory found that certain nanoviricides eliminated 99.99% of the virus from infected cells.
A video excerpt of the interview can be found at 2theadvocate.com | News | Possible progress in herpes treatment -- Baton Rouge, LA. The video was also linked to the front page of The Drudge Report, DRUDGE REPORT 2009(R).
The LSU School of Veterinary Medicine has received a grant of $11.1M in July 2009, adding to a previous award of $9.9M in 2004, for the LSU Center of Biomedical Research Excellence (COBRE) from the National Institutes of Health (NIH). Konstantin G. Kousoulas, PhD, Professor of Veterinary Virology and Director of BIOMMED, is the administrator of the COBRE program at the LSU School of Veterinary Medicine. He is also the Mary Louise Martin Professor of Virology and the Director of LSU-Tulane Center for Experimental Infectious Disease Research.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM